Clinical Study Report (CSR) Synopses

Lilly provides the ability to search for Clinical Study Report (CSR) Synopses for Phase 2, Phase 3 and Phase 4 clinical trials that initiated on or after October 15, 2002, and studied the effects of medicines that are approved for use in the United States (U.S.) and the European Union (EU).

Lilly is working to complete the transfer of these CSR Synopses from different sources and will continue to update the search with historical trials. Newly completed studies will be provided in a timely manner for approved medicines after the approval of an indication has occurred in the U.S. and the EU and the primary peer-reviewed publication is available.

The information is not intended to replace the advice of your physician and is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Lilly products. If you have any questions regarding any information contained in this link, please consult with your physician.

Trade Name Generic Name
Adcirca ® Tadalafil
Alimta ® Pemetrexed
Cialis  ® Tadalafil
Cymbalta ® Duloxetine
Cyramza ® Ramucirumab
Effient ® Prasugrel
Evista ® Raloxifene
Forteo ® Teriparatide
Gemzar ® Gemcitabine
Glucagon ™ Glucagon (Injection)
Humalog ® Human Insulin Lispro
Humatrope ® Somatropin
Humulin ® Human Insulin
Lartruvo ™ Olaratumab
Portrazza ® Necitumumab
Prozac ® Fluoxetine
Strattera ® Atomoxetine
Symbyax ® Olanzapine and Fluoxetine
Taltz ® Ixekizumab
Trulicity ™ Dulaglutide
Yentreve ® Duloxetine
Zyprexa ® Olanzapine

Search CSR Synopses